#Repligen
Case study: How Repligen ensures stable bioprocessing with Eilersen digital capacitive load cells

Eilersen Electric Digital Systems A/S (Denmark) - How Repligen ensures stable bioprocessing with Eilersen digital capacitive load cells From fermentation to purification, Eilersen’s digital capacitive…
Case study: How Repligen ensures stable bioprocessing with Eilersen digital capacitive load cells
Eilersen Electric Digital Systems A/S (Denmark) - How Repligen ensures stable bioprocessing with Eilersen digital capacitive load cells From fermentation to purification, Eilersen’s digital capacitive load cells provide Repligen with accurate, reliable measurements that enable fewer deviations, more consistent batches, less downtime and easier validation. Repligen: Enabling Global Bioprocessing with Digital Accuracy: Repligen is a global bioprocessing-focused life sciences company known for their high-quality products and innovative technologies.
blog.hoasenvang.com.vn
November 12, 2026 at 4:30 AM
🚨 $RGEN
On November 6, 2026, in connection with the consummation of previously announced private exchange and subscription transactions, Repligen Corporation issued $1.0 billion aggregate principal amount of its 0.25% Convertible Senior Notes due 2031 under an Indenture, dated November 6, 2026 , ...
SEC Filing: RGEN
Click to view the official SEC document.
www.sec.gov
November 6, 2026 at 9:03 PM
🚨 $RGEN
On October 30, 2026, Repligen Corporation issued a press release announcing the entry into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 and certain new investors, pursuant to which the Company ...
SEC Filing: RGEN
Click to view the official SEC document.
www.sec.gov
October 30, 2026 at 10:13 AM
Random Stock
Ticker: $RGEN
Company: Repligen Corporation
Sector: Healthcare
Industry: Medical Instruments & Supplies
# Employees: 2,000
Recent Close: $175.80
52-Week High: $198.87
52-Week High Date: 09-28-2026
% Off 52-Week High: -11.60%
52-Week Low: $100.99
October 28, 2026 at 5:00 AM
📑 Repligen published 2026 Q3 earnings call deck
📈 Watsco releases Q3 2026 financial results report
📑 Dorman Products published 2026 Q3 earnings deck
📑 PayPal Holdings published 2026 Q3 earnings deck
October 27, 2026 at 5:53 PM
REPLIGEN #RGEN EARNINGS HIGHLIGHTS

🔹 Revenue: $209.00M
🔹 Adj. EPS: $0.53
🔹 GAAP EPS: $0.68
🔹 Gross Margin: 53.0%

FY 2026 Guide:
🔹 Total Reported Revenue: $844M - $852M
🔹 Reported Growth: 14.5% - 15.5%
🔹 Organic Growth: 12% - 13%

Other Q Metrics:
🔹 Operating Income

https://financier.news/
October 27, 2026 at 12:19 PM
Repligen $RGEN reported Q3 2026 Adj EPS of $0.53, beating the $0.46 estimate by 15.2%. Revenue of $209.3M beat the $206.7M estimate by 1.3%.

https://fundspec.ai/s/RGEN/earnings
Know who reports today, with an AI probability of a beat or a miss.
October 27, 2026 at 11:10 AM
🚨 $RGEN
On October 27, 2026, Repligen Corporation announced its financial results for the third quarter ended September 30, 2026. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this F...
SEC Filing: RGEN
Click to view the official SEC document.
www.sec.gov
October 27, 2026 at 11:04 AM
Repligen ($RGEN): 13G holder update
FMR LLC: now 13% (about $1.3B)
SEC Schedule 13G/A · filed Oct 7
#Investing #Stocks

Follow @elixstocksdata for daily institutional & insider activity.
FMR LLC: 13% of Repligen ($RGEN)
Schedule 13G/A filed Oct 7. Who filed, the stake, and how it changed.
elixstocks.com
October 7, 2026 at 3:49 PM
📄 #RGEN 10-Q — what changed
MD&A now says: "Management's Discussion and Analysis of Financial Condition and Results of Operations 19"
📈 Full redline → https://www.formdelta.com/ticker/RGEN

#10Q #RGEN #StockMarket
FormDelta — Insider Trading Alerts
What REPLIGEN CORP changed in their own words, quarter over quarter.
www.formdelta.com
October 6, 2026 at 8:20 PM
$RGEN — Merger/Acquisition

Repligen Corporation (RGEN) completed its acquisition of BioLife Solutions, Inc. (BLFS), a cell processing tools and services provider for the cell and gene therapy market.

🧵 continued ↓
October 6, 2026 at 4:45 PM
▲ $RGEN Repligen Corp : Completed acquisition of BioLife Solutions; BioLife's CryoStor® portfolio supports 18 approved cell therapies and majority of U.S. cell-based trials; high-margin consumables business highly complementary; expects to detail FY2026 i...
October 6, 2026 at 5:15 PM
BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock. The acquisition expands Repligen's presenc...

🚀 Free alerts → https://gunpowderalerts.com/go?utm_source=bluesky&utm_medium=social&utm_campaign=high_priority_filing
#Investing #FinancialDisclosure #8K
October 6, 2026 at 4:45 PM
▲ $RGEN Repligen: Merger with AIRE values company at $1.0B net value ($10.00/share), pending shareholder vote Oct 5; two lawsuits filed to enjoin deal, but management expects closure by Q1 2027; strategic expansion into U.S. bioprocessing. [BULLISH]
October 1, 2026 at 1:33 AM
📊 Daily USA Market Intelligence — Oct 1
50 filings · 24 HIGH · 26 MEDIUM

Today's digest reveals a market bifurcated between AI-driven growth stories (e.g., **Fortrea**, **Repligen**) and value-trap financials (e.g., **Chiba Bank**).

#Finance #Alpha #SECfilings

🧵 See Thread ↓
October 1, 2026 at 1:33 AM
Repligen Raises Guidance to 13.5% on Organic Growth

Repligen raised its full-year organic growth outlook to a range of 10.5% to 13.5% following a second-quarter performance that outpaced prior expecta…

Read more: https://embers.news/article/repligen-raises-guidance-to-135-on-organic-growth-64445
Repligen Raises Guidance to 13.5% on Organic Growth
Repligen raised its full-year organic growth outlook to a range of 10.5% to 13.5% following a second-quarter performance that outpaced prior expectations despite persistent headwinds in gene therapy and filtration segments, management announced at the Wells Fargo 21st Annual Healthcare Conference.
embers.news
September 20, 2026 at 3:06 PM
🚨 $RGEN
On September 10, 2026, Karen A. Dawes notified Repligen Corporation that she will be retiring from the Repligen Board of Directors after over twenty years of distinguished service to Repligen, effective as of September 30, 2026. Ms. Dawes commented, “It has been a privilege and an honor t...
SEC Filing: RGEN
Click to view the official SEC document.
www.sec.gov
September 15, 2026 at 8:04 PM